Compare Box Inc (BOX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Summit Therapeutics Inc — how do they compare? Box Inc trades at $33.57 (market cap $4.48B), while Summit Therapeutics Inc trades at $14.01 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.7× Box Inc's market cap, and Box Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BOX | SMMT | |
|---|---|---|
Market Cap | $4.48B | $12.06B |
Sector | Technology | Health |
52-Week High | $33.64 | $26.98 |
52-Week Low | $21.37 | $12.55 |
Enterprise Value | $5.03B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX Inc. (NYSE: BOX) trades at $33.64, up 2.47% with a bullish technical signal. The company reported strong revenue growth to $1.09 billion in 2025 and net income of $244.62 million, with improving profit margins. Analyst consensus is bullish with 17 buy ratings and a $37.00 price target. Recent news highlights Box's AI security enhancements and enterprise partnerships, including Quintas Energy's platform selection.
The outlook remains positive given revenue growth and margin expansion, but risks include competitive pressures and debt levels. Upside potential exists if Box maintains its digital transformation momentum, though investors should monitor execution against earnings expectations and macroeconomic impacts on tech spending.
Summit Therapeutics (SMMT) trades at $15.10, showing minimal daily change. The technical outlook is bullish based on moving averages, though the stock faces critical FDA review for its lead drug ivonescimab by November 2026. Recent news includes regulatory approval in China and expanded clinical trials, but the company reports significant losses and negative cash flow from operations, highlighting its pre-revenue biotech status.
The investment case hinges on ivonescimab's regulatory success, with a consensus price target of $24.18 implying substantial upside. However, high execution risk, ongoing losses, and a shareholder investigation present significant challenges. The stock offers high-risk, high-reward potential for speculative investors banking on positive clinical and regulatory outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
